Company intelligence / Profile preview

Adapt Pharma

Dublin, Ireland

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Adapt Pharma developed and commercialized NARCAN (naloxone HCl) Nasal Spray, the first and leading intranasal naloxone product for emergency treatment of opioid overdose. NARCAN Nasal Spray achieved FDA approval in 2015 (4mg formulation) and was commercialized in major markets before Adapt Pharma was acquired by Emergent BioSolutions in 2018. Clinical data established intranasal naloxone as an effective, easy-to-administer, life-saving treatment with broad uptake among first responders and in community programs.

Therapeutic areas: Neurology
Modalities: Small moleculeDevice
Industry: Biotech

Beyond the preview

Go deeper on Adapt Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adapt Pharma.

Explore the full profile